Actionable perturbations in the DNA damage response establish synergistic therapeutic routes in ATM deficient pancreatic cancer
Objectives Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-associated death in the Western World. PDAC bears a high accumulation of oncogenic mutations. Recent sequencing studies found Ataxia-Telangiectasia Mutated (ATM) frequently mutated in PDAC. Our lab previously showed that the loss of ATM accelerates EMT and promotes genomic instability (Russell, Nature communication, 2013; Perkhofer, 2017, Cancer Research). In line with the altered genomic integrity of ATM-mutated PDAC established genotype specific strategies like PARP- and ATR- inhibition.
Source: Pancreatology - Category: Gastroenterology Authors: Johann Gout, Lukas Perkhofer, Frank Arnold, Thomas Seufferlein, Pierre-Oliver Frappart, Alexander Kleger Tags: 9. Experimental pancreatic cancer I Source Type: research
More News: Adenocarcinoma | Ataxia | Cancer | Cancer & Oncology | Gout | Pancreas | Pancreatic Cancer | Study